Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation

D Rachmilewitz, F Karmeli, L W Schwartz, P L Simon

Abstract
The effect of 5-ASA and 4-ASA, drugs used for the treatment of inflammatory bowel disease, on modulation of experimental colitis and on colonic generation of interleukin-1 was evaluated. Three weeks of treatment with 5-ASA or 4-ASA (50 μg/kg) and one week of treatment with 5-ASA significantly decreased colonic interleukin-1 generation and the extent and severity of inflammation in a rat model of colitis induced by trinitrobenzene sulphonic acid. Colonic biopsies were obtained from patients with active ulcerative colitis and organ cultured 24 hours in the absence or presence of the following drugs: sulphasalazine, sulpyridine, 5-ASA and 4-ASA (25–100 μg/ml). Interleukin-1 content in tissue cultured in the presence of 5-ASA (100 μg/ml) was two-thirds of its content in tissue cultured in drug free medium and its release into the medium was decreased by 50%. Sulphasalazine 50 μg/ml significantly decreased by 33% the tissue content but did not affect interleukin-1 release and a higher dose was not more effective. Sulpyridine and 4-ASA in doses up to 100 μg/ml did not affect either interleukin-1 colonic content or its release into the culture medium. We conclude that pharmacological suppression of colonic interleukin-1 generation may be one, although not the sole mechanism to explain the therapeutic efficacy of 5-ASA in the treatment of inflammatory bowel disease.

Recent studies have suggested a possible role of interleukin-1 in the pathogenesis of inflammatory bowel disease and experimental colitis. Peripheral blood mononuclear cells of Crohn's disease patients were shown to produce in vitro high quantities of interleukin-1 compared with normal control cells and enhanced production of interleukin-1 beta was shown in colonic mononuclear cells of patients with inflammatory bowel disease. We have shown enhanced production of interleukin-1 by organ cultured colonic mucosa of patients with ulcerative colitis and Crohn's disease, most of which is derived from stimulated lamina propria mononuclear cells.

Interleukin-1 was shown also in three models of experimental colitis: in the chronic rat model of trinitrobenzene sulphonic acid induced colitis; in the rabbit immune complex colitis; and in a rabbit model of acute colitis induced by enteropathogenic E. coli.

In view of the enhanced colonic generation of interleukin-1 in models of experimental colitis and in patients with active inflammatory bowel disease and its possible contribution to the pathogenesis of the disease, it was logical to assume that drugs used in the treatment of inflammatory bowel disease may affect the generation of this cytokine. Corticosteroids which block interleukin-1 production by macrophages were shown to inhibit its content as well as its release from the inflamed colonic mucosa of patients with ulcerative colitis. A dual cyclooxygenase inhibitor was shown to decrease colonic interleukin-1 synthesis in an experimental model of chronic colitis in rats.

The aim of the present study was to evaluate the possible modulation of experimental colitis by 5-ASA and 4-ASA and to determine the effect of sulphasalazine, its moieties, sulpyridine and 5-ASA and 4-ASA on human colonic generation of interleukin-1 and, thus, to assess whether interference with its generation may be contributory to their therapeutic effects.

Methods

COLITIS INDUCTION IN RATS
All of the animal studies described in this report adhere to the standards established by the Guide for the care and use of laboratory animals (HHS NIH Pub No 85-21).

Non-fasted male Sprague Dawley rats, 200–250 g body weight, were used. Inflammation of the colon was induced, as previously described, under light ether anaesthesia by a single intracolonic administration of 0–25 ml 50% ethanol containing 30 mg of trinitrobenzene sulphonic acid (Sigma, St Louis, MO, USA). The solution was introduced through a 0.3 mm (od) catheter at a distance of 7 cm from the anus. Rats were treated daily for one or three weeks after the induction of colonic injury with 5-ASA (50 mg/kg) or with 4-ASA (50 mg/kg). Drugs were dissolved in 1% methylcellulose and were administered intragastrically. Control rats were treated intragastrically with 50 ml/kg of the vehicle (methylcellulose) daily. Rats were humanely killed one or three weeks after the induction of colonic injury. The colon was isolated, a 5 cm segment of the distal colon proximal to the anus was resected, its lumen rinsed with ice cold saline and weighed. A cross section was obtained for histology, fixed in phosphate buffered formaldehyde, embedded in paraffin and routine 5 μ sections were prepared. Tissues were routinely stained with haematoxylin and eosin and evaluated by light microscopy. The remaining mucosa was scraped, minced and kept at -70°C. Samples of these mucosal scrapings were processed for determination of TxB2, LTB4, myeloperoxidase activity and interleukin-1.
Determination of Myeloperoxidase Activity and Eicosanoids

Mucosal tissue specimens were obtained during fibreoptic colonoscopy from inflamed sites in the rectosigmoid colon of patients with untreated active ulcerative colitis. The diagnosis of ulcerative colitis was established according to clinical, endoscopic, pathologic, and radiologic criteria. In all patients clinical activity was manifested by bloody diarrhoea and verified histologically by the presence of mucosal ulceration, crypt abscesses, and infiltration with inflammatory cells. No subjects had received any medication for at least two weeks before the biopsies were obtained. The study protocol was approved by the local hospital's Helsinki Committee. Four to five tissue samples obtained from the same subject were incubated, each in a separate dish, immediately after excision in the absence or presence of sulphasalazine, sulphapyridine, 5-ASA (Pharmacia Laboratories, Uppsala, Sweden) or 4-ASA (Reed-Carnerick, New Jersey, USA) 25–100 µg/ml. 5-ASA and sulphasalazine were dissolved in DMSO (stock solution 100 mg/ml). Working dilutions were prepared in Roswell Park Memorial Institute (RPMI) medium, final pH 7.5 identical to that of RPMI. 4-ASA was dissolved in double distilled water, but this was not technically significant (Table I). During treatment only one of the 5-ASA treated rats died after 10 days of treatment. None of the trinitrobenzene sulphonate acid/ethanol treated rats. In the 5-ASA treatment group, the wet weight was lower than in untreated rats but the difference did not reach statistical significance (Table I). After one week of treatment the severity of the trinitrobenzene sulphonate acid/ethanol induced lesions was evaluated macroscopically to be reduced in six of eight 5-ASA treated rats. At this time interval the wet weight of the affected segments was reduced but this was not statistically significant (Table II). During treatment only one of the 5-ASA treated rats died after 10 days of treatment. None of the trinitrobenzene sulphonate acid/ethanol or 4-ASA treated rats died during the three week follow up period.

The effect of three weeks' drug treatment was evaluated histopathologically in 10 rats which served as untreated trinitrobenzene sulphonate acid/50% ethanol injured subjects, and in 19 rats which received trinitrobenzene sulphonate acid/50% ethanol injury plus drug treatment. A single blind evaluation of the histopathological lesions resulted in the accurate identification of five of 10 untreated rats and identification of 16/19 rats.
which received drug treatment. This suggests that the reduction in lesion severity by drug treatment reduces lesion severity and allows its identification. A similar histological evaluation was completed of eight rats receiving 5-ASA for one week. Ten trinitrobenzene sulphonic acid/50% ethanol treated rats served as untreated controls. A single blind evaluation of the severity and extent of the histopathological changes after one week resulted in identification of seven of 10 untreated rats and accurate identification of five of eight treated controls, suggesting that one week of treatment with 5-ASA also reduced lesion severity.

Mucosal myeloperoxidase activity was not different in the control trinitrobenzene sulphonic acid/ethanol treated rats and in the 5-ASA and 4-ASA treatment groups (Tables I, II). The generation of the eicosanoids Tx B2 and LT B4 was also not affected after three weeks of treatment with 5-ASA or 4-ASA, or after one week of treatment with 5-ASA (Tables I, II). On the other hand, after three weeks of therapy with 5-ASA and 4-ASA a significant decrease in mucosal interleukin-1 was observed when compared with trinitrobenzene sulphonic acid/ethanol treated rats receiving no drugs (Table I). One week of treatment with 5-ASA reduced mucosal interleukin-1 levels but not significantly (Table II).

**EFFECT OF DRUGS ON HUMAN COLONIC INTERLEUKIN-1**

After 24 hours of culture, interleukin-1 content in the cultured tissue specimens was 53 ± (6.3) μg/mg wet weight and its accumulation in the cultured medium was 12.4 ± (1.7) units/mg wet weight×(SE) (n = 12). The effect of the drugs (100 μg/ml) on mucosal interleukin-1 content and its release to the medium is presented in the Figure. Mucosal interleukin-1 content and its release in cultures conducted in drug free medium was regarded as 100%. Only 5-ASA significantly decreased interleukin-1 colonic content and its release during 24 hours of culture. Interleukin-1 content in colonic mucosa cultured in the presence of 5-ASA was two-thirds of its content in tissue cultured in drug free medium. Interleukin-1 release into the medium containing 5-ASA was 50% of its release when cultured in drug free medium. 5-ASA concentrations lower than 100 μg/ml had no effect (Table III). Sulphasalazine (50 μg/ml) significantly decreased interleukin-1 content but did not significantly affect its release into the medium. A higher concentration of 100 μg/ml did not further decrease the tissue content and also did not affect its release into the medium (Table III). Sulphapyridine and 4-ASA did not significantly affect either interleukin-1 content in the mucosa or its release into the culture medium.

**Discussion**

We have previously shown that the interleukin-1 bioassay used in the present study is in good correlation with an enzyme linked immunoassorbent (ELISA) assay and that substances
derived from the homogenisation did not interfere with the bioassay. Using this bioassay we have shown that colonic interleukin-1 generation is significantly increased in two models of experimental colonic inflammation and that interleukin-1 content in cultured mucosa of ulcerative colitis and Crohn's disease patients, and its release into the medium is several folds higher than their respective content and release by normal colonic mucosa. Prednisolone was found to decrease the human colonic tissue content of interleukin-1 and, even more effectively, to decrease its release into the medium during culture.

In the present study, using the same methodology, 5-ASA was found to effectively decrease human colonic content of interleukin-1 and also to effectively decrease its release into the medium during culture. Similar observations were recently reported by Mahida et al. 5-ASA is the active moiety in salazopyrine and when administered by itself is effective in the treatment of mild to moderate active ulcerative colitis and in the maintenance of the disease in remission. 5-ASA was previously shown to also inhibit the generation of human colonic prostanooids, leukotrienes, and the platelet activating factor - potential mechanisms to explain its therapeutic effects.

The injury induced by trinitrobenzene sulfonic acid/ethanol is definitely extensive. It is difficult to anticipate that any drug would be able to prevent the development of the inflammatory response to this severe insult, to modify its propagation or the generation of the inflammatory mediators. Yet, in the present study, 5-ASA was found to significantly affect interleukin-1 generation, although none of the other mediators determined - TxB2 and LTB4. In addition, the majority of rats treated with 5-ASA could be blindly identified, both macroscopically and histologically, indicating its therapeutic effect. It, therefore, seems that 5-ASA is a potent inhibitor of interleukin-1 generation, which may definitely contribute towards its antiinflammatory properties.

Sulphasalazine had no effect on human colonic interleukin-1 generation whereas sulphasalazine significantly decreased only its tissue content but did not affect its release. Sulphasalazine does not affect the generation of any of the other inflammatory mediators and is not considered effective in the treatment of inflammatory bowel disease. Sulphasalazine, on the other hand, inhibits, although to a lesser extent than 5-ASA, the generation of colonic eicosanoids, and the platelet aggregation factor. As the therapeutic efficacy of sulphasalazine and 5-ASA is similar, it would appear that this efficacy cannot only be ascribed to their effects on one or all of the inflammatory mediators. Yet, if inhibition of the generation of inflammatory mediators is of importance only, 5-ASA share with corticosteroids significant inhibition of the colonic generation of prostanooids, leukotrienes, the platelet aggregation factor and, as has been shown, also of interleukin-1.

4-ASA is also claimed to be of benefit in the treatment of ulcerative colitis. The mechanism responsible for its therapeutic efficacy is not well defined. In the present study it was found to modulate an experimental model of chronic colitis in which it significantly decreased colonic interleukin-1 generation but had no effect on human colonic interleukin-1 generation. The discrepancy between the effect of 4-ASA on human and rat colonic interleukin-1 generation casts doubts on the importance of blocking the generation of colonic interleukin-1 as the sole, important mechanism to explain the therapeutic effects of 4-ASA as well as the other drugs currently used for the treatment of inflammatory bowel disease.

Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation.

D Rachmilewitz, F Karmeli, L W Schwartz and P L Simon

Gut 1992 33: 929-932
doi: 10.1136/gut.33.7.929

Updated information and services can be found at:
http://gut.bmj.com/content/33/7/929

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Ulcerative colitis (1113)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/